UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 17, 2024

Aura Biosciences, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware (State or Other Jurisdiction of Incorporation)

001-40971 (Commission File Number)

80 Guest Street Boston, Massachusetts (Address of Principal Executive Offices) (IRS Employer Identification No.) 02135

32-0271970

(Zip Code)

Registrant's Telephone Number, Including Area Code: 617 500-8864

Not Applicable (Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

□ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Dere-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, \$0.00001 par value per share	AURA	The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company \boxtimes

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. \Box

Item 7.01. Regulation FD Disclosure.

On October 17, 2024, Aura Biosciences, Inc. (the "Company") announced positive early data from its ongoing Phase 1 clinical trial of bel-sar (AU-011) in patients with non-muscle-invasive bladder cancer ("NMIBC"). The Company issued a press release announcing this update titled "Multiple Clinical Complete Responses Demonstrated Following Single Low Dose Administration of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) in Ongoing Phase 1 Trial". A copy of the press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.

The information furnished under this Item 7.01, including Exhibit 99.1 hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 8.01 Other Events.

On October 17, 2024, the Company hosted a virtual urologic oncology investor event to present early NMIBC data from its ongoing Phase 1 trial. A copy of the presentation from this event is filed as Exhibit 99.2 for purposes of Section 18 of the Exchange Act.

Forward Looking Statements

Statements contained under this Item 8.01 regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements about the initiation, timing, progress, results and cost of the Company's research and development programs and the Company's current and future preclinical studies and clinical trials, including statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available and the Company's research and development programs; statements regarding the Company's expectations for an improved quality of life of patients after treatment with bel-sar and changes to the treatment paradigm for patients; statements regarding the company's beliefs and expectations for the high unmet medical need for an effective local treatment in urologic oncology to preserve organ function; and the size and growth potential of the markets for the Company's product candidates and the Company's ability to serve those markets.

Any forward-looking statements are neither promises nor guarantees, and investors should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond the Company's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements, including, without limitation, uncertainties inherent in clinical trials and in the availability and timing of data from ongoing clinical trials; the expected timing for submissions for regulatory approval or review by governmental authorities; the risk that the results of the Company's preclinical trials may not be predictive of future results in connection with future clinical trials; the risk that interim or early data from ongoing clinical trials may not be predictive of final data from completed clinical trials; the risk that governmental authorities may disagree with the Company's clinical trial designs even where the Company has obtained agreement with governmental authorities on the design of such trials; whether the Company's cloned trials or to market products; whether the Company's cash resources will be sufficient to fund its foreseeable and unforeseeable operating expenses and capital expenditure requirements; the Company's ongoing and planned preclinical activities; and the Company's ability to initiate, enroll, conduct or complete ongoing and planned clinical trials. These risks, uncertainties, and other factors include those risks and uncertainties described under the heading "Risk Factors" in the Company's most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the United States Securities and Exchange Commission ("SEC") and in subsequent filings made by the Company or therwise. These forward-looking statements are based on the Company's current expectations and speak only as of the date hereof and no representations or warranties (express or implied) are made about the

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No. Description

- 99.1 Press Release Dated October 17, 2024.
- 99.2 Virtual Urologic Oncology Investor Event Presentation of the Company
- 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Aura Biosciences, Inc.

Date: October 17, 2024

Ву:

/s/ Elisabet de los Pinos Elisabet de los Pinos President and Chief Executive Officer

Multiple Clinical Complete Responses Demonstrated Following Single Low Dose Administration of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) in Ongoing Phase 1 Trial

Clinical Complete Responses Observed in 4 out of 5 Patients in Subset of Patients with Low Grade Disease; Evidence of Bladder Urothelial Field Effect in Non-Target Tumors

Favorable Safety Profile Observed; Only Grade 1 Drug-Related Adverse Events Reported in Less Than 10% of Patients

Aura Hosting Virtual Urologic Oncology Investor Event with Key Opinion Leaders at 4.30 pm ET Today

BOSTON, MA - October 17, 2024 - <u>Aura Biosciences</u>, Inc. (NASDAQ: AURA), today announced positive early data from an ongoing Phase 1 clinical trial of bel-sar (AU-011) in patients with NMIBC. To date, the trial includes 13 patients, with the primary endpoints of evaluating the safety and feasibility of local administration of bel-sar alone (n=5) and bel-sar with light activation (n=8). The secondary endpoints are to evaluate biological activity and immune mediated changes in the tumor microenvironment (TME). 10 of 13 study participants had low grade disease, approximating the 70% incidence of this patient population among all NMIBC patients. The other 3 study participants had high grade disease. In patients receiving bel-sar with light activation (n=8), 4 out of 5 patients with low grade disease demonstrated a clinical complete response with no tumor cells remaining on histopathological evaluation. 2 out of 3 patients with high grade disease demonstrated visual tumor shrinkage observed on cystoscopy. Aura will host a <u>Virtual Urologic Oncology Investor Event</u> at 4:30 pm ET today.

"We are highly encouraged by this positive early data, which shows that bel-sar has the potential to be a transformative cancer treatment," said Sabine Brookman-May, MD, FEBU, Senior Vice President, Therapeutic Area Head Urologic Oncology of Aura Biosciences. "A potentially differentiating aspect of this novel treatment is the rapid tumor response accompanied by an immune oncology (IO) effect such as a marked CD8+ T-cell infiltration observed in just a matter of days with a single low dose. We believe this could have the potential to translate into a durable response. In parallel with expanding the ongoing Phase 1 trial, we are preparing for a Phase 2 trial to further evaluate bel-sar's clinical activity and durability of response."

"Bel-sar has the potential to change the treatment paradigm for NMIBC," said Neal Shore, MD, FACS, Medical Director, Carolina Urologic Research Center, AUC Urology Specialists. "Based on this early data, bel-sar's positive clinical activity and evidence of a bladder urothelial field effect with a single dose, may position bel-sar to be the first immune ablative treatment option for early-stage bladder cancer patients delivered with an in-office procedure." Bel-sar is a virus-like drug conjugate, designed to have a dual mechanism of action, that induces direct tumor cell necrosis and elicits a robust and durable anti-tumor immune response.

Trial Design: The ongoing Phase 1 trial (<u>NCT05483868</u>) is a two-part, open-label clinical trial, designed to assess the safety and feasibility of bel-sar as a monotherapy. The study treatment is administered 7 to 12 days before the scheduled transurethral resection of bladder tumor (TURBT), the standard of care procedure. The participants are followed for safety monitoring over a 56-day period. The trial is also evaluating bel-sar's biological activity with histopathological evaluation of tissue samples collected at the time of TURBT (regardless of tumor response) with evaluation of focal necrosis and immune changes in the tumor microenvironment. Part 1 (n=5) of the trial is complete, with patients receiving a single bel-sar dose without light activation. Part 2 (n=10) of the trial is ongoing. 8 patients with a confirmed tumor at time of treatment have received either 100ug or 200ug of bel-sar as a single dose. Of these 8 patients, 5 had low grade disease and 3 had high grade disease. 7 of these 8 patients had a history of recurrent bladder cancer and had undergone multiple TURBTs and adjuvant treatments such as Bacillus Calmette-Guerin (BCG), mitomycin, gemcitabine, cetrelimab and tamoxifen prior to trial enrollment. In the Phase 1 trial expansion, Aura plans to test additional doses and treatment regimens.

Safety Data: In the safety analysis as of the September 9, 2024 data cut-off date (n=12), bel-sar was well-tolerated, with less than 10% of patients reporting Grade 1 and no Grade 2 or higher drug-related adverse events reported. No serious adverse events have been reported. No significant differences between the light-activated and non-light activated cohorts have been observed.

Biological Activity: The data in these 8 patients receiving bel-sar with light activation showed clinical activity detectable as soon as 7 days after a single low dose of bel-sar with light activation. This was demonstrated by histopathological evidence of clinical complete response, necrosis, immune activation or visual tumor shrinkage observed on cystoscopy. For this analysis, "clinical complete response" was defined as the absence of tumor cells on histopathologic evaluation. Of the patients with low-grade disease, 4 out of 5 exhibited a clinical complete response (1 of 4 based on local pathology with central review ongoing), with no tumor cells detected in histopathological evaluation post-treatment in the target and in several non-target bladder tumors. 2 of 3 of the patients with high grade disease demonstrated visual tumor shrinkage observed on cystoscopy, while tumor cells were still present on histopathological evaluation. Immune activation was noted in all patients in both treated target and untreated non-target bladder tumors with infiltration of effector CD8+ and CD4+ T-cells (where immune staining was available). This data provides evidence of a bladder urothelial field effect with a single low dose of bel-sar with light activation, potentially indicating a broader immune response in the bladder beyond the target tumor in these patients.

Aura Virtual Urologic Oncology Investor Event

Aura will host a Virtual Urologic Oncology Investor Event featuring Max Kates, MD (Johns Hopkins), Joe Jacob, MD (Syracuse University), Neal Shore, MD (Carolina Urologic Research Center) and Gary Steinberg, MD (RUSH University) to discuss the early Phase 1 data on Thursday, October 17, 2024, at 4:30 pm Eastern Time. To register for the event, click <u>here</u>. A live question and answer session will follow the formal discussion.

The live webcast of Aura's Virtual Urologic Oncology Investor Event will be available on the "Investors & Media" page under the "Events & Presentations" section of Aura's website at https://ir.aurabiosciences.com/events-and-presentations, where a replay of the webcast will be archived for 90 days following the presentation date.

About Aura Biosciences

Aura Biosciences is a clinical-stage biotechnology company focused on developing precision therapies for solid tumors that aim to preserve organ function. Our lead candidate, bel-sar (AU-011), is currently in late-stage development for primary choroidal melanoma and in early-stage development in other ocular oncology indications and bladder cancer. Aura Biosciences is headquartered in Boston, MA. Our mission is to grow as an innovative global oncology company that positively transforms the lives of patients.

For more information, visit aurabiosciences.com. Follow us on X (formerly Twitter) @AuraBiosciences and visit us on LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, and other federal securities laws. Any statements that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "may," "will," "could," "expects," "intends," "plans," "anticipates," "believes," "endeavor," "projects," "sreeks," "endeavor," "potential," "could," the meaning of the Private Securities Litigation Reform Act of 1995, as amended, and other federal securities laws. Any statements that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "may," "will," "could," "should," "expects," "intends," "plans," "anticipates," "believes," "endeavor," potential," "continue" or the negative of such words or other similar expressions can be used to identify forward-looking statements. These forward-looking statements regarding Aura's future expectations, plans and prospects, including, without limitation, statements regarding the therapeutic potential of bel-sar for the treatment of cancers including bladder cancer; statements regarding Aura's plans and expectations for the ongoing Phase 1 and future trials of bel-sar for bladder cancer; statements regarding Aura's beliefs and expectations for bel-sar's ability to provide durable responses in bladder cancer patients; statements regarding Aura's expectations for an improved quality of life of patients after treatment with bel-sar and changes to the treatment paradigm for patients; statements regarding Aura's beliefs and expectations for the high unmet medical need for an effective local treatment in urologic oncology; and statements regarding Aura's expectations for the estimated patient populations and related market opportunities for bel-sar.

The forward-looking statements in this press release are neither promises nor guarantees, and investors should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors, many of which are beyond Aura's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements, including, without limitation, uncertainties inherent in clinical trials and in the availability and timing of data from ongoing clinical trials; the expected timing for submissions for regulatory approval or review by governmental authorities; the risk that the results of Aura's preclinical and clinical trials may not be predictive of future results in connection with future clinical trials; the risk that eray data from ongoing clinical trials; the risk that governmental authorities; may isagree with Aura's clinical trial designs; whether Aura will receive regulatory approvals to conduct trials or to market products; whether Aura's cash resources will be sufficient to fund its foreseeable and unforeseeable operating expenses and capital expenditure requirements; Aura's ongoing and planned preclinical activities; and Aura's ability to initiate, enroll, conduct or complete ongoing and planned clinical trials. These risks, uncertainties and other factors include those risks and uncertainties described under the heading "Risk Factors" in Aura's most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the United States Securities and Exchange Commission (SEC) and in subsequent filings made by Aura with the SEC, which are available on the SEC's webite at <u>www.sec.gov</u>. Except as required by law, Aura disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Aura's current expectations and speak onl

Investor Contact: Alex Dasalla

Head of Investor Relations and Corporate Communications IR@aurabiosciences.com

Media Contact:

Kimberly Ha KKH Advisors <u>kimberly.ha@kkhadvisors.com</u> 917-291-5744



To innovate the future of cancer care to cure patients and preserve organ function

Legal disclosure

This presentation contains forward-looking statements, all of which are qualified in their entirety by this cautionary statement. Many of the forward-looking statements contained herein can be identified by the use of forward-looking words such as "may", "anticipate", "believe", "could, "expect", "should", "plan", "intend", "estimate", "will", "potential" and "ongoing", among others, although not all forward-looking statements contain these identifying words. These forward-looking statements include statements about the initiation, timing, progress, results and cost of our research and development programs and our current and future preclinical studies and clinical trials, including statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available and our research and development programs; statements for an improved quality of life of patients after treatment with bel-sar and changes to the treatment paradigm for patients; statements regarding our beliefs and expectations for the high unmet medical need for an effective local treatment in urologic oncology to preserve organ function; and the size and growth potential of the markets for our product candidates and our ability to serve those markets.

Except as otherwise noted, these forward-looking statements speak only as of the date of this presentation, and we undertake no obligation to update or revise any of such statements to reflect events or circumstances occurring after this presentation. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these forward-looking statements as predictions of future events. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in our most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC), as well as discussions of potential risks, uncertainties, and other important factors in our other subsequent filings with the SEC, which are available on the SEC's website at www.sec.gov. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. We caution you not to place undue reliance on the forward-looking statements contained in this presentation.

This presentation discusses product candidates that are under preclinical or clinical evaluation and that have not yet been approved for marketing by the U.S. Food and Drug Administration (FDA) or any other regulatory authority. Until finalized in a clinical study report, clinical trial data presented herein remain subject to adjustment as a result of clinical site audits and other review processes. No representation is made as to the safety or effectiveness of these product candidates for the use for which such product candidates are being studied.

This presentation shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

Urologic oncology key opinion leaders participating on today's call



Max Kates, MD Johns Hopkins



Joe Jacob, MD, MCR Syracuse University



Neal Shore, MD, FACS Carolina Urologic Research Center



Gary Steinberg, MD, FACS RUSH University

aura 🖪

Aura leadership participating on today's call



Sabine Brookman-May, MD SVP, Therapeutic Area Head Urologic Oncology



Elisabet de los Pinos, PhD Founder and CEO



Jill Hopkins, MD Chief Medical Officer And President of R&D



Joseph McQuaid, MD Director, Clinical Development Urologic Oncology

Cancer cases are predicted to increase by 77% by 2050 as our population ages and grows¹

Large increase in the number of early-stage cancers requiring treatment options with improved benefit-risk profile

1. World Health Organization. Global cancer burden growing, amidst mounting need for services. 2024. Available at: Global cancer

Growing need for functionpreserving, organ-sparing, local therapies that can intercept the course of disease

d for services (who.int) (Accessed October 1, 2024).

Virus-like drug conjugates have the potential to transform early cancer treatment




Unique tumor selectivity

Targets a key receptor molecule expressed in the early stages of malignant tumor transformation

Dual MOA

Targeted cytotoxicity and immune activation; potential to generate lasting anti-tumor T-cell memory



Tumor and mutation-agnostic

>100 cell lines >15 animal tumor models

High potency

~200 cytotoxic molecules per VLP; demonstrated picomolar efficacy in multiple animal tumor models

Positive clinical data in multiple early-stage local cancers

- Choroidal melanoma: Positive phase 2 data; phase 3 ongoing
- NMIBC: Positive early phase 1 data; phase 1 ongoing

Favorable safety profile


No treatment-related SAEs and no DLTs reported in bel-sar Phase 2 choroidal melanoma trial

auro


VLPs bind to macrophages, B cells, dendritic cells and neutrophils and are capable of stimulating antigen-presenting cells through TLR-4 engagement and NFk-β production

AU-011 has a novel dual mechanism of action


Disruption of the tumor cell membrane and pro-immunogenic cell death by necrosis leads to T cell activation and immunemediated tumor cell killing



Bladder cancer: High unmet medical need for function-preserving organ-sparing therapies



High risk of recurrence and progression with current treatments for NMIBC



 "Each figure represents 1000 persons.
 Holzbeierlein JM et al. J Urol. 2024;212(1):3–10.2.
 Leur Urol. 2009;56(3):430–42.
 BCG, Bacillus Calmette-Guérin; CIS, carcinoma in si a in situ: IR, in sk: NMIRC e bladder cancer; TURBT, transurethral resection of bla

aura 🔋

Treatment goals

AU-011 as a potential front-line immune ablative therapy in NMIBC

AU-011 has a dual mechanism of action and can potentially reduce the treatment burden



Focal treatment with direct tumor cell killing

Stimulate broad anti-tumor T cell response

Front-line early intervention for local disease

Decreased treatment burden with favorable safety profile

Reduce risk of recurrence and progression

Avoid TURBT/operating room

BC, non-muscle-invasive bladder cancer; TURBT, transurethral resection of bladder tumor.

In-office procedure

AU-011 administration and activation may be optimized for the urology clinic

Local administration of AU-011 is aligned with current practice in urology offices



<5 minutes

Laser light activation

<10 minutes total laser time

<15 minutes total procedure time

Familiar procedures for urologists Bladder injections (e.g. botox) and laser application are commonly used

No general anesthesia

AU-011 treatment may be feasible for patients with contraindications for general anesthesia/TURBT (e.g., comorbidities)



No requirement for additional safety precautions in drug handling No viral replication or shedding


n of bladder tu

Phase 1 trial of AU-011 in bladder cancer

Review of early data from non-light activated and light-activated NMIBC cohorts


Window of opportunity study: AU-011 administered between scheduled biopsy and standard TURBT

Clinical response data up to 21 days; safety data up to 56 days



TURBT, transurethral resection of bladder tumor. Clinicaltrials.gov identifier: NCT05483868; AU-011-102


Phase 1 trial of AU-011 for bladder cancer designed to evaluate safety, feasibility, and mechanism of action



NMIBC, non-muscle-invasive bladder cancer; MoA, mechanism of action; TURBT, transurethral resection of Clinicaltrials.gov identifier: NCT05483868; AU-011-102.



Phase 1 trial of AU-011 for bladder cancer designed to evaluate safety, feasibility, and mechanism of action



aura


NMIBC, non-muscle-invasive bladder cancer; MoA, mechanism of action; TURBT, transuret Clinicaltrials.gov identifier: NCT05483868; AU-011-102.

Drug only without light activation (n=5)

Drug only: Treatment schedule

Total dose: 100 µg

- 50 μg into base of tumor
- 50 μg into lamina propria



H&E, hematoxylin and eosin; TURBT, transurethral resection of bladder Clinicaltrials.gov identifier: NCT05483868; AU-011-102.

Drug only: Safety data

First in human in bladder – safety cohort as required by FDA


Drug only without light activation (n=5)

Safety Data

vent	Grade	Number of patients
dverse events (related	to study drug)	
one	None	0/5
dverse events (related	to injection or laser procedure)	
ematuria	1	1/5
 No treatment emergent adverse events related to study drug No serious adverse events No dose limiting toxicities 		

ClinicalTrials.gov Identifier: NCT06007690; AU-011-301. FDA, Food and Drug Administration

Phase 1 trial of AU-011 for bladder cancer designed to evaluate safety, feasibility, and mechanism of action



aura

NMIBC, non-muscle-invasive bladder cancer; MoA, mechanism of action; TURBT, transurethral resectio Clinicaltrials.gov identifier: NCT05483868; AU-011-102.


Cohort A-C: Single-dose drug with light activation (n=~10)

Cohorts A–C: Single-dose drug with light activation

Treatment schedule

Cohort A:

- 50 µg into base of tumor
- 50 μg into lamina propria Cohort B:
- 100 μg into base of tumor Cohort C:
- 200 µg into base of tumor



Cohort A + B: Single-dose drug with light activation (n=7)^a

Cohort A + B: Single-dose drug with light activation

Safety data

- No serious adverse events
- No dose limiting toxicities

Event	Grade	Number of patients		
Adverse events (related to study drug)				
Nocturia	1	1/7		
Urinary urgency	1	1/7		
Adverse events (related to injection or laser procedure)				
Hematuria	1	1/7		
Urinary blood clots	1	1/7		
Nocturia	1	1/7		
Urinary urgency	1	1/7		

Favorable safety profile:

<10% of patients experienced Grade 1 TEAEs related to study drug; no Grade 2/3 adverse events related to study drug (n=12)

ACompiled safety data includes all completed light-activated cohorts (A and B). Data cutoff date of September 9, 2024. TEAE, treatment-emergent adverse event. Clinicaltrials.gov identifier: NCT05483868; AU-011-102.

Efficacy data: Ta low-grade 4/5 low-grade target tumors demonstrate complete response to AU-011

	Patient A1	Patient A3	Patient A4°	Patient B2	Patient C1 ^d
Screening diagnosis	Single (Multiple at TURBT) Ta low-grade	Multiple Ta low-grade	Multiple Ta low-grade (2024) Ta high-grade (2023)	Multiple Ta low-grade	Multiple Ta low-grade
Screening AUA risk classification	Low	Intermediate	Intermediate	Intermediate	Intermediate
AU-011 dose/delivery	100 μg IT/IM	100 µg IT/IM	100 µg IT/IM	100 µg IT	200 µg IT
Clinical complete response: Target tumorª	~	~	~	-	~
Clinical complete response: Non-target tumor ^a (bladder urothelial field effect ^b)	2/2	1/2	1/1	-	-
Immune response ^e : Target tumor	~	~	~	~	pending
Immune response ^e : Non-target tumor	~	~	~	~	pending
Necrosis	~	~	~	-	pending
Visual changes on cystoscopy	~	~	-	~	~

Cohorts A-C:

Single-dose drug with light activation

*For purposes of this analysis, Clinical complete response defined as absence of tumor cells on histopathologic evaluation. *Bladder urothelial field effect: absence of tumor cells in non-target lesion «Previously treated tumor demonstrated high-grade disease but pathology at time of treatment revealed low-grade disease in non-target tumor. *Complete response (target tumor) based upon local pathology with central review ongoing: immume response and necrosis evaluations pending central review. * Immume response is defined by immunocyte infiltration on post-treatment histopathology AUA, American Urological Association; M, Intratumoral; TURBT, transurethral resection of bladder tumor. Clinicaltrials.gov identifier: NCT05483868; AU-011-102. aura 22

Light-activated cohorts (A + B):

Strong evidence of immune-mediated mechanism of action

- 100% (7/7) of target tumors showed infiltration of effector CD8+T and CD4+ cells, as early as 7 days after laser activation
- 100% (7/7) of non-target tumors^a (in the five patients with available immune staining) showed T cell infiltration, supportive of a bladder urothelial field effect
- Focal eosinophilic infiltration was observed in 57% (4/7) target tumors and in 14% (1/7) non-target tumors, supportive of a local innate immune response to tumor necrosis
- Generation of lymphoid follicles^b was observed in 71% (5/7) target tumors, supportive of a local adaptive immune response

AU-011 showed evidence of producing pro-immunogenic changes in situ that have the potential to bridge, activate, and enhance adaptive immunity, consistent with its expected MOA

*Patients for which biopsies were available. ^bOrganized aggregates of immune cells. MOA, mechanism of action Clinicaltrials.gov identifier: NCT05483868; AU-011-102.

Patient A1

64-year-old Caucasian male

Screening diagnosis: (2023)

Single Ta low-grade <3 cm No CIS

Screening AUA risk classification: Low

Initial diagnosis: (2010)

Single Ta low-grade <3 cm No CIS

Low risk
 Prior TURBT:


2011; 2012; 2018

- Prior adjuvant therapies: MMC (2011)
- Tamoxifen (2016)
- Gemcitabine (2018)

Cohort A:

Single-dose drug with light activation

Complete clinical response visualized at time of TURBT confirmed with histopathologic evaluation



CIS, carcinoma in situ; H&E, hematoxylin and eosin; MMC, mitomycin C; TURBT, transurethral resection of bladder tumor. Clinicaltrials.gov identifier: NCT05483868; AU-011-102.

Patient A1

64-year-old Caucasian male

creening di	agnosis: (202	:3)	
Single			
	ade <3 cm		
No CIS			
Screening A	UA risk clas	sification:	
Low			
Initial diagn	osis: (2010)		
 Single 			
 Ta low-gra 	ide <3 cm		
 No CIS 			
 Low risk 			
Prior TURB	:		
2011; 2012;	2018		
Prior adjuva	int therapies		
• MMC (20	11)		
Tamoxife	า (2016)		
 Gemcitat 	oine (2018)		

Summary of pre-and-post treatment pathology: Single low-grade target lesion and two non-target lesions

Pre-treatment pathology	Post-treatment pathology	
Target lesion: Clinical complete response		
 Local pathology: Papillary urothelial carcinoma, non-invasive, low- grade Muscularis propria not identified Note – no central pathology 	Central pathology: Negative for urothelial carcinoma Chronic inflammation 	
Non-target lesion A & B: Abse	ence of tumor cells (2/2 lesions)	
Not applicable: No pre-treatment specimen obtained 	Central pathology: Negative for urothelial carcinoma Chronic inflammation 	

Clinical complete response (target lesion)^a

Bladder urothelial field effect^b


Cohort A:

Single-dose drug with light activation

*Clinical complete response identified on histopathologic evaluation. *Bladder urothelial field effect: absence of tumor in non-target lesions. AUA, American Urological Association; CIS, carcinoma in situ; MMC, mitomycin C; TURBT, transurethral resection of bladder tumor. ClinicalTrials.gov identifier: NCT06007690; AU-011-301.

Patient A1: AU-011 focal distribution, necrosis, and positive immune staining (target lesion)

Post-treatment



Cohort A: Single-dose drug with light activation No central pathology read available for pre-treatment; block lost at site. H&E, hematoxylin and eosin. Clinicaltrials.gov identifier: NCT05483868; AU-011-102

Patient A3

72-year-old Hispanic male

Screening diagnosis: (2024) Multiple Ta low-grade (<3 cm) No CIS

Screening AUA risk classification: Intermediate


Initial diagnosis: (2019) Ta high-grade <3 cm No CIS Intermediate risk

Prior TURBT:


2019, 2020 (x2), 2021 (x2), 2023

Prior adjuvant therapies: BCG induction and maintenance (2020-2021)

Complete clinical response visualized at time of TURBT confirmed with histopathologic evaluation



Pre-injection/pre-biopsy appearance of tumor on office cystoscopy



Post-injection edema and ecchymosis at injection site

Cohort A: Single-dose drug with light activation AUA, American Urological Association; BCG, Bacillus Calmette-Guerin; CIS, carcinoma in situ; TURBT, transurethral resection of bladder tumor. Clinicaltrials.gov identifier: NCT05483868; AU-011-102.

Patient A3

72-year-old Hispanic male

Screening diagnosis: (2024) Multiple Ta low-grade (<3 cm) No CIS
Screening AUA risk classification: Intermediate
Initial diagnosis: (2019)
Ta high-grade <3 cm
No CIS
Intermediate risk
Prior TURBT:
2019, 2020 (x2), 2021 (x2), 2023
Prior adjuvant therapies:
 BCG induction and maintenance
(2020-2021)

Summary of pre-and-post treatment pathology: Single low-grade target lesion and two non-target lesions

Pre-treatment pathology	Post-treatment pathology
Target lesion: Clinica	al complete response
Central pathology: Low-grade papillary urothelial carcinoma, non-invasive 	Central pathology: Negative for urothelial carcinoma Acute and Chronic inflammation
Non-target lesion A and B: absence of tu	mor cells (A) / immune cell infiltration (B)
LESION A Not applicable: Pre-treatment biopsy not completed	LESION A Central pathology: • Negative for urothelial carcinoma • Chronic inflammation
LESION B Not applicable: Pre-treatment biopsy not completed	LESION B Central pathology: Papillary urothelial carcinoma; non-invasive Low-grade Additional findings: Cystitis cystica et glandularis

Clinical complete response (target lesion)^a


Bladder urothelial field effect^b

Cohort A:

Single-dose drug with light activation


*Clinical complete response identified on histopathologic evaluation. *Bladder urothelial field effect: absence of tumor in non-target lesions. AUA, American Urological Association; BCG, Bacillus Calmette-Guerin; CIS, carcinoma in situ; TURBT, transurethral resection of bladder tumor. Clinicaltrials.gov identifier: NCT05483868; AU-011-102.

Patient A3: AU-011 focal distribution, necrosis, and positive immune staining (target lesion)



Cohort A: Single-dose drug with light activation H&E, hematoxylin and eosin. Clinicaltrials.gov identifier: NCT05483868; AU-011-102

Patient A3: Post-treatment generation of secondary lymphoid follicles and increase in CD3, CD4, and CD8 infiltration



Cohort A: Single-dose drug with light activation

H&E, hematoxylin and eosin. Clinicaltrials.gov identifier: NCT05483868: AU-011-102

Efficacy data: Ta high-grade 3/3 high-grade tumors demonstrated immune response to AU-011

	Patient A2	Patient B1	Patient B3	
Screening diagnosis	Single Ta high-grade	Multiple Ta high-grade	Single Ta high-grade	
Screening AUA risk classification	High	High	Intermediate	
AU-011 dose/ delivery	100 µg IT/IM	100 µg IT	100 µg IT	
Clinical complete response: Target tumor ^a	-	-	-	
Clinical complete response: Non-target tumorª (bladder urothelial field effect ^b)	NA	-	NA	
Immune response ^c : Target tumor	~	~	~	
Immune response ^c : Non-target tumor	NA	~	NA	
Necrosis	-		-	
Visual changes on cystoscopy	Tumor Visually Smaller	Tumor Visually Smaller	-	


Cohorts A + B:

Single-dose drug with light activation


*Clinical complete response defined as absence of tumor cells on histopathologic evaluation.*Bladder urothelial field effect: absence of tumor cells in non-target lesions. Immune response is defined by immunocyte infiltration on post-treatment histopathology AUA, American Urological Association; BCG, Bacillus Calmette-Guerin; CIS, carcinoma in situ; IM, intramural; IT, intratumoral; TURBT, transurethral resection of bladder tumor. Clinicaltrials.gov identifier: NCT05483868; AU-011-102.



AU-011 demonstrated a favorable safety profile with robust clinical and immunological response in early data readout of 'all-comers' NMIBC patients



AE, adverse event; DLT, dose-limiting toxicity; DOR, duration of response; MOA, mechanism of action; NMIBC, non-muscle-invasive bladder cancer; SAE, serious adverse event ClinicalTrials.gov Identifier: NCT06007690; AU-011-301.






Anti-tumor immunity: Treating beyond the target

Preclinical development




Where does AU-011 fit in the cancer immunity cycle and the TME sub-cycle?



PC, antigen-presenting cell; CTL, cytotoxic T lymphocyte; DAMPs, damage-associated molecular patterns; IDC, immature dendritic cell; MDSC, myeloid-derived uppressor cell; ROS, reactive oxygen species; TAM, tumor-associated macrophage; TLS, tertiary lymphoid structures; TME, tumor microenvironment.

Role of CD4+ and CD8+ T-cells at time of treatment and time of tumor rechallenge in the TC-1 syngeneic murine tumor model




Robust pre-clinical activity in bladder cancer both as a single agent and in combination with checkpoint inhibitors

AU-011 treatment impacts primary and distant tumors, overall survival, and induction of durable immunological memory

- Treatment resulted in complete response and prevented tumor growth after rechallenge
- Data supports potential prevention of metastatic disease


IP. int

al: IV. intravenous: NIR.



Tumor growth

Survival



Syngeneic mouse tumor bladder model

- MB49 model in C57BL/6 mice N = 8-10/group

Anti-PD-1


Mouse equivalent of pembrolizumab 100 µg administered 3 times every 3 days (IP)

AU-011

- 100 µg as a single dose (IV)
 All groups tracted and the set of the set All groups treated with NIR (50 J/cm²)

All animals that survived the first treatment were rechallenged and survival was evaluated up to 100 days after rechallenge

Survival after rechallenge



Patient A1: Single-dose drug with light activation Immunohistochemistry

Stain		Target lesion		Non-target lesion A		Non-target lesion B	
		Pre-treatment	Post-treatment	Pre-treatment	Post-treatment	Pre-treatment	Post-treatment
AU-011		NA	Absent	NA	Absent	NA	Absent
Necrosi	s	NA	Present	NA	Absent	NA	Absent
CD3	Intratumoral	NA	NA	NA	NA	NA	NA
	Stromal	NA	Moderate	NA	Moderate	NA	Moderate
	Benign urothelial	NA	NA	NA	Mild	NA	Mild
	Lymphoid follicle	NA	Marked	NA	Marked	NA	Marked
CD4	Intratumoral	NA	NA	NA	NA	NA	NA
	Stromal	NA	Moderate	NA	Moderate	NA	Moderate
	Benign urothelial	NA	NA	NA	Absent	NA	Absent
	Lymphoid follicle	NA	Marked	NA	Marked	NA	Marked
CD8	Intratumoral	NA	NA	NA	NA	NA	NA
	Stromal	NA	Mild	NA	Mild	NA	Mild
	Benign urothelial	NA	NA	NA	Mild	NA	Mild
	Lymphoid follicle	NA	Moderate	NA	Moderate	NA	Moderate
CD45	Intratumoral	NA	NA	NA	NA	NA	NA
	Stromal	NA	Marked	NA	Moderate	NA	Moderate
	Benign urothelial	NA	NA	NA	Mild	NA	Mild
	Lymphoid follicle	NA	Marked	NA	Marked	NA	Marked

NA, not applicable. Clinicaltrials.gov ide

Clinicaltrials.gov identifier: NCT05483868; AU-011-102

Patient A3: Single-dose drug with light activation Immunohistochemistry

Stain		Target lesion (biopsy)		Target lesion (TURBT)		Non-target lesion A		Non-target lesion B	
		Pre-treatment	Post- treatment	Pre-treatment	Post- treatment	Pre-treatment	Post- treatment	Pre-treatment	Post- treatment
AU-011		Absent	Present	Absent	Absent	NA	Absent	NA	Absent
Necrosi	s	Absent	Absent	Absent	Present	NA	Absent	NA	Absent
CD3	Intratumoral	Mild	NA	Mild	NA	NA	NA	NA	Mild
	Stromal	Mild	Moderate	Mild	Moderate	NA	Mild	NA	Mild
	Benign urothelial	Mild	Mild	Mild	Mild	NA	Mild	NA	Mild
	Lymphoid follicle	NA	Marked	NA	Marked	NA	NA	NA	NA
CD4	Intratumoral	Absent	NA	Absent	NA	NA	NA	NA	Absent
	Stromal	Mild	Moderate	Mild	Moderate	NA	Mild	NA	Mild
	Benign urothelial	Absent	Mild	Absent	Mild	NA	Absent	NA	Mild
	Lymphoid follicle	NA	Marked	NA	Marked	NA	NA	NA	NA
CD8	Intratumoral	Mild	NA	Mild	NA	NA	NA	NA	Mild
	Stromal	Mild	Mild	Mild	Mild	NA	Mild	NA	Mild
	Benign urothelial	Mild	Mild	Mild	Mild	NA	Mild	NA	Mild
	Lymphoid follicle	NA	Mild	NA	Mild	NA	NA	NA	NA
CD45	Intratumoral	Mild	NA	Mild	NA	NA	NA	NA	Mild
	Stromal	Mild	Moderate	Mild	Moderate	NA	Moderate	NA	Moderate
	Benign urothelial	Mild	Mild	Mild	Mild	NA	Mild	NA	Mild
	Lymphoid follicle	NA	Marked	NA	Marked	NA	NA	NA	NA

NA, not applicable; TURBT, transurethral resection of bladder tumor Clinicaltrials.gov identifier: NCT05483868; AU-011-102.

Patient A3

72-year-old Hispanic male

Screening diagnosis: (2024)

Multiple **Ta low-grade (<3 cm)** No CIS

Screening AUA risk classification: Intermediate


Initial diagnosis: (2019) Ta high-grade <3 cm No CIS Intermediate risk

Prior TURBT:

2019, 2020 (x2), 2021 (x2), 2023

Prior adjuvant therapies: BCG induction and maintenance (2020-2021)

Secondary (activated) lymphoid follicle: Capable of generating tissue-specific, adaptive immune responses



- Secondary lymphoid follicles form ectopically at sites of chronic inflammation and antigenic stimulation
- Lymphoid follicles are widely reported in colorectal and ovarian carcinoma, suggestive of ongoing B-cell expansion and a favorable prognosis

Cohort A: Single-dose drug with light activation AUA, American Urological Association; BCG, Bacillus Calmette-Guerin; CIS, carcinoma in situ; TURBT, transurethral resection of bladder tumor. Clinicaltrials.gov identifier: NCT05483868; AU-011-102.